Abstract:Zika virus represents the primary cause of infection during pregnancy and can lead to various neurological disorders such as microcephaly and Guillain-Barré syndrome affecting both children and adults. This infection is also associated with urological and nephrological problems. So far, evidence of mosquito-borne Zika virus infection has been reported in a total of 89 countries and territories. However, surveillance efforts primarily concentrate on outbreaks that this virus can cause, yet the measures implemented are typically limited. Currently, there are no specific treatments or vaccines designed for the prevention or treatment of Zika virus infection or its associated disease. The development of effective therapeutic agents presents an urgent need. Importantly, an alternative for advancing the discovery of new molecules could be dermaseptins, a family of antimicrobial peptides known for their potential antiviral properties. In this study, we carried out the synthesis of dermaseptins and their analogs and subsequently assessed the bioactivity tests against Zika virus (ZIKV PF13) of dermaseptins B2 and S4 and their derivatives. The cytotoxicity of these peptides was investigated on HMC3 cell line and HeLa cells by CellTiter-Glo® Luminescent Cell Viability Assay. Thereafter, we evaluated the antiviral activity caused by the action of our dermaseptins on the viral envelope using the Fluorescence Activated Cell Sorting (FACS). The cytotoxicity of our molecules was concentration-dependent at microgram concentrations Expect for dermaseptin B2 and its derivative which present no toxicity against HeLa and HMC3 cell lines. It was observed that all tested analogs from S4 family exhibited antiviral activity with low concentrations ranging from 3 to 12.5 μg/ml , unlike the native B2 and its derivative which increased the infectivity. Pre-incubating of dermaseptins with ZIKV PF13 before infection revealed that these derivatives inhibit the initial stages of virus infection. In summary, these results suggest that dermaseptins could serve as novel lead structures for the development of potent antiviral agents against Zika virus infections.

Identification of desoxyrhapontigenin as a novel antiviral agent against congenital Zika virus infection

Identification Of Novel Natural Products As Effective And Broad-Spectrum Anti-Zika Virus Inhibitors

Design, Synthesis, and Biological Evaluation of a Series of New Anthraquinone Derivatives As Anti-Zikv Agents.

Cathelicidin-Derived Antimicrobial Peptides Inhibit Zika Virus Through Direct Inactivation and Interferon Pathway.

Design, synthesis, and antiviral activity of 1-aryl-4-arylmethylpiperazine derivatives as Zika virus inhibitors with broad antiviral spectrum

Evaluation of the antiviral activity of new dermaseptin analogs against Zika virus

Nonsteroidal Anti-Inflammatory Drugs Potently Inhibit The Replication Of Zika Viruses By Inducing The Degradation Of Axl

Sevsrvg Selectively Delivers Antiviral Sirna to Fetus Brain, Inhibits ZIKV Infection and Mitigates ZIKV-induced Microcephaly in Mouse Model

Zika Virus Propagation and Release in Human Fetal Astrocytes Can Be Suppressed by Neutral Sphingomyelinase-2 Inhibitor GW4869

Insight into the Natural Biomolecules (BMs): Promising Candidates as Zika Virus Inhibitors

Design, Synthesis, and Biological Evaluation of Novel 2'-Methyl-2'-fluoro-6-methyl-7-alkynyl-7-deazapurine Nucleoside Analogs As Anti-Zika Virus Agents.

Investigation of novel 5ʹ-amino adenosine derivatives with potential anti-Zika virus activity

Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles

Identification of Novel Non-Nucleoside Inhibitors of Zika Virus NS5 Protein Targeting MTase Activity

Discovery And Computational Analyses Of Novel Small Molecule Zika Virus Inhibitors

Repurposing of Doramectin As a New Anti-Zika Virus Agent

A Peptide-Based Viral Inactivator Inhibits Zika Virus Infection in Pregnant Mice and Fetuses.

Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus

JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo

Generation of A Stable GFP-reporter Zika Virus System for High-throughput Screening of Zika Virus Inhibitors

In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus